B+
Bull case
20%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
XFOR
X4ANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The September 8 FDA interaction materially improves the 4WARD setup by reducing the required sample size while preserving stated statistical power, potentially shortening enrollment and lowering execution burden. X4 also had a reported $208.0 million cash position at June 30, 2026 and has emerging European XOLREMDI commercialization support [#PR-EARNINGS-2026-08-06].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +20.5.
What can break
4WARD enrollment may not complete by year-end 2026, and topline data are not expected until the first half of 2028.
Momentum
19
Value
41
Sentiment
98
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.75 · Bull $8.00 · Bear $2.10Analysis 2026-09-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $11.60
Why
Momentum19 · Δ7d -4.2
Value41 · Δ7d 0.0
Sentiment98 · Δ7d +20.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +20.5.
Contradictions & invalidation
- • 4WARD enrollment may not complete by year-end 2026, and topline data are not expected until the first half of 2028.
- • Clinical development, commercialization, and potential financing or dilution risk remain material for a low-coverage small-cap biotech.
- • The principal value driver remains an unproven Phase 3 trial with enrollment still expected only by year-end 2026 and topline data not expected until the first half of 2028.
Catalyst clock
2026-08-12
Insider open-market sales
Lead driver: Sentiment · See AI snapshot
Momentum
19
9% active weight
Current posture
7d trendSoftening
Δ7d
-4.2
Δ21d
-43.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
98
62% active weight
Current posture
7d trendImproving
Δ7d
+20.5
Δ21d
+20.0
Why this grade
Composite grade A. Momentum 18.7 / Value 41.2 / Sentiment 98.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-09. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.75
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.10
Analysis reference price unavailable
Analysis 2026-09-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$426.33M
Beta
0.46
Shares Out
99.15M
P/E (TTM) · Derived
-2.3
P/S (TTM)
9.88
P/FCF (TTM) · Derived
-0.65
Rev YoY
+346.3%
EPS YoY
-96.3%
Gross Margin
+80.8%
Op Margin
-554.7%
Net Debt
-$176.52M
Current Ratio
11.30
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data